40% of patients need Theralase treatment.This article dated July 2024.
BCG Treatment for Bladder Cancer: What You Need to Know Merck is actively working on building new manufacturing facility, through it will be several years before it is creating BCG.
60% of patients do not have their bladder cancer come back after BCG treatment, but 40% of the time cancer come back within two years. Several years before Merck is creating BCG, mean that Theralase has plenty of time to get to the finish line before the BCG shortage problem has been resolved.
The 40% of patients that have their cancer come back, are the patients that Theralase treatment is trying to help.
Even if the BCG shortage was resolved, this 40% will still be there for theralase to treat.